Jim Cramer gave a cautious nod to Immunome (IMUN) on January 8, 2026, stating investors can speculate on the biotech stock if they choose, signaling potential short-term interest. The comment comes as IMUN trades near $12.45, up 8.3% in the past week.
- IMUN traded at $12.45 on January 8, 2026, up 8.3% weekly
- Average daily volume rose to 1.2 million shares, double the 30-day average
- Options activity shows a spike in call volume, reaching a 14-day high
- Immunome’s Phase 2 trial for IMU-838 remains a key near-term catalyst
- No profitable quarter reported in the last three fiscal years
- Cramer’s comment reflects growing retail speculation in high-beta biotech stocks
Jim Cramer addressed Immunome (IMUN) during a live segment on January 8, 2026, acknowledging the company’s speculative profile in the biotechnology sector. While offering no endorsement of its long-term fundamentals, Cramer said, 'If you want to speculate on it, fine,' suggesting that retail traders may find short-term momentum in the name. The stock, currently trading at $12.45, has seen a weekly gain of 8.3%, outpacing the broader biotech index’s 2.1% advance over the same period. The biotech sector remains volatile amid ongoing regulatory scrutiny and mixed clinical trial outcomes. Immunome, focused on developing novel immunotherapies for autoimmune and inflammatory diseases, has not reported a profitable quarter in the past three fiscal years. Its pipeline includes Phase 2 trials for IMU-838, a monoclonal antibody targeting the IL-17 pathway, which remains under evaluation. Market activity reflects Cramer’s remarks, with IMUN’s average daily trading volume rising to 1.2 million shares—nearly double its 30-day average. Options volume has also spiked, with call contracts at a 14-day high. These indicators suggest heightened retail interest, particularly among momentum-driven investors seeking exposure to high-beta biotech names. The commentary underscores a broader trend in retail markets: the increasing influence of media figures on speculative trading behavior. While no major institutional positions were disclosed in the latest 13F filings, the stock’s price action indicates growing attention. Investors are advised to consider the risks associated with early-stage biotech equities, including high volatility and dependence on single clinical milestones.